BIOMAT Database Logo BIOMAT Database Logo

ICRF-159: current status and clinical prospects. 1977

R E Bellet, and M Rozencweig, and D D Von Hoff, and J S Penta, and T H Wasserman, and F M Muggia

UI MeSH Term Description Entries
D007970 Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000). Leukocytopenia,Leukocytopenias,Leukopenias
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008223 Lymphoma A general term for various neoplastic diseases of the lymphoid tissue. Germinoblastoma,Lymphoma, Malignant,Reticulolymphosarcoma,Sarcoma, Germinoblastic,Germinoblastic Sarcoma,Germinoblastic Sarcomas,Germinoblastomas,Lymphomas,Lymphomas, Malignant,Malignant Lymphoma,Malignant Lymphomas,Reticulolymphosarcomas,Sarcomas, Germinoblastic
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D009325 Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D011929 Razoxane An antimitotic agent with immunosuppressive properties. ICRF-159,ICRF-186,NSC-129943,Razoxane Mesylate, (R)-Isomer,Razoxane, (R)-Isomer,Razoxin,ICRF 159,ICRF 186,ICRF159,ICRF186,NSC 129943,NSC129943
D012004 Rectal Neoplasms Tumors or cancer of the RECTUM. Cancer of Rectum,Rectal Cancer,Rectal Tumors,Cancer of the Rectum,Neoplasms, Rectal,Rectum Cancer,Rectum Neoplasms,Cancer, Rectal,Cancer, Rectum,Neoplasm, Rectal,Neoplasm, Rectum,Rectal Cancers,Rectal Neoplasm,Rectal Tumor,Rectum Cancers,Rectum Neoplasm,Tumor, Rectal
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon

Related Publications

R E Bellet, and M Rozencweig, and D D Von Hoff, and J S Penta, and T H Wasserman, and F M Muggia
Editoral: ICRF 159.
March 1974, Lancet (London, England),
R E Bellet, and M Rozencweig, and D D Von Hoff, and J S Penta, and T H Wasserman, and F M Muggia
Letter: ICRF 159.
May 1974, Lancet (London, England),
R E Bellet, and M Rozencweig, and D D Von Hoff, and J S Penta, and T H Wasserman, and F M Muggia
Letter: ICRF 159.
March 1974, Lancet (London, England),
R E Bellet, and M Rozencweig, and D D Von Hoff, and J S Penta, and T H Wasserman, and F M Muggia
Bis-diketopiperazine derivatives in clinical oncology: ICRF-159.
January 1980, Cancer clinical trials,
R E Bellet, and M Rozencweig, and D D Von Hoff, and J S Penta, and T H Wasserman, and F M Muggia
[Clinical experiences with radiotherapy and ICRF 159 in sarcomas].
January 1978, Strahlentherapie. Sonderbande,
R E Bellet, and M Rozencweig, and D D Von Hoff, and J S Penta, and T H Wasserman, and F M Muggia
[ICRF 159--a cytostatic substance].
October 1978, Deutsche medizinische Wochenschrift (1946),
R E Bellet, and M Rozencweig, and D D Von Hoff, and J S Penta, and T H Wasserman, and F M Muggia
Razoxane (ICRF 159) in psoriasis.
December 1976, Lancet (London, England),
R E Bellet, and M Rozencweig, and D D Von Hoff, and J S Penta, and T H Wasserman, and F M Muggia
Cumulative cytostatic effect of ICRF 159.
February 1974, Nature,
R E Bellet, and M Rozencweig, and D D Von Hoff, and J S Penta, and T H Wasserman, and F M Muggia
in vitro effects of ICRF 159.
July 1973, British journal of cancer,
R E Bellet, and M Rozencweig, and D D Von Hoff, and J S Penta, and T H Wasserman, and F M Muggia
A clinical evaluation of ICRF 159 as a radiosensitising agent.
January 1978, International journal of radiation oncology, biology, physics,
Copied contents to your clipboard!